Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

JOHNS HOPKINS UNIVERSITY

🇳🇦Namibia

Country: 🇳🇦Namibia

Ownership: -

Established: 1876-01-01

Employees: 19.4K

Market Cap: -

Website: https://www.jhu.edu/

Clinical Trials

Levetiracetam and Memory Function in Amnestic Mild Cognitive Impairment (MCI)

Phase 2

Completed

Conditions: Mild Cognitive Impairment (MCI)

Interventions: Drug: Levetiracetam 62.5mg
Drug: Levetiracetam 125mg
Drug: Levetiracetam 250mg
Drug: Placebo

First Posted Date: 2010-01-08

Last Posted Date: 2017-08-21

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 96

Registration Number: NCT01044758

Locations: 🇺🇸
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States

A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis

Phase 4

Completed

Conditions: Pulmonary Arterial Hypertension
Pulmonary Hypertension
Systemic Sclerosis
Scleroderma Spectrum of Diseases
Connective Tissue Disease

Interventions: Drug: tadalafil and ambrisentan upfront combination therapy

First Posted Date: 2010-01-05

Last Posted Date: 2017-09-12

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 25

Registration Number: NCT01042158

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

Contingency Management in the Delivery of HAART to Drug Users in Chennai, India

Phase 2

Completed

Conditions: HIV
Substance Abuse, Intravenous

Interventions: Behavioral: Contingency
Other: Prize bowl drawings

First Posted Date: 2009-12-15

Last Posted Date: 2016-11-02

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 120

Registration Number: NCT01031745

Locations: 🇮🇳
YR Gaitonde Centre for Substance Abuse-Related Research (YRGCSAR), Chennai, Tamil Nadu, India

Eculizumab to Enable Renal Transplantation in Patients With History of Catastrophic Antiphospholipid Antibody Syndrome

Phase 2

Completed

Conditions: Antiphospholipid Antibody Syndrome
End Stage Renal Disease

Interventions: Drug: Eculizumab

First Posted Date: 2009-12-10

Last Posted Date: 2020-10-26

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 1

Registration Number: NCT01029587

Locations: 🇺🇸
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States

Safety and Immunologic Effect of Low Dose Versus High Dose Vitamin D3 in Multiple Sclerosis

Phase 1

Completed

Conditions: Multiple Sclerosis
Vitamin D Deficiency

Interventions: Drug: Cholecalciferol

First Posted Date: 2009-12-03

Last Posted Date: 2013-02-06

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 40

Registration Number: NCT01024777

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission

Phase 4

Completed

Conditions: Tourette Syndrome

Interventions: Drug: Placebo
Drug: Riluzole
Drug: D-serine

First Posted Date: 2009-11-23

Last Posted Date: 2018-01-30

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 39

Registration Number: NCT01018056

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

Safety and Tolerability of the Ketogenic Diet in Amyotrophic Lateral Sclerosis (ALS)

Phase 3

Terminated

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Dietary Supplement: KetoCal

First Posted Date: 2009-11-19

Last Posted Date: 2015-04-01

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 1

Registration Number: NCT01016522

Locations: 🇺🇸
Johns Hopkins ALS Clinic, Baltimore, Maryland, United States

Compare the Effects of Fluticasone Furoate Nasal Spray vs Placebo in Patients With Nasal Polypoid Disease

Phase 4

Terminated

Conditions: Patients With Nasal Polyps

Interventions: Other: placebo
Drug: fluticasone furoate

First Posted Date: 2009-11-16

Last Posted Date: 2017-09-13

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 7

Registration Number: NCT01013701

Doxycycline Outcomes in Lupus Erythematosus

Phase 4

Withdrawn

Conditions: Cardiovascular Disease

Interventions: Drug: Placebo
Drug: Doxycycline

First Posted Date: 2009-11-16

Last Posted Date: 2012-03-30

Lead Sponsor: Johns Hopkins University

Registration Number: NCT01014260

Locations: 🇺🇸
Johns Hopkins University SOM. 1830 East Monument St, Ste 7500, Baltimore, Maryland, United States

Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience

Not Applicable

Completed

Conditions: Cystic Fibrosis

Interventions: Other: Cystic Fibrosis Education
Behavioral: Motivational Interviewing

First Posted Date: 2009-11-16

Last Posted Date: 2015-03-31

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 128

Registration Number: NCT01013896

Locations: 🇺🇸
Johns Hopkins, Baltimore, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy